You searched for ips cell - Page 3 of 273

Weekend reads: ES cell research polls well, Gordie Howe, MS, IPS cells, and more

June 10, 2016 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Here are some headlines & articles worth a look and some thought on stem cell and biomedical science more generally. Gallup finds in a new poll that 60% of Americans surveyed find human embryonic stem celsl research “largely acceptable”. On the other hand human reproductive cloning is highly frowned upon, sandwiched in the “highly unacceptable […]

Weekend reads: ES cell research polls well, Gordie Howe, MS, IPS cells, and more Read More »

Good stem cell news as Masayo Takahashi IPS Cell Trial to Resume

June 7, 2016 / Professor Paul Knoepfler, Ph.D. / 9 Comments

Some good news today as the pioneering induced pluripotent stem (IPS) cell trial led by Dr. Masayo Takahashi will resume. This clinical study with a focus on macular degeneration has been on hold for quite some time due to regulatory changes in Japan. There had also been concerns over mutations in the 2nd patient’s IPS

Good stem cell news as Masayo Takahashi IPS Cell Trial to Resume Read More »

Pain in a dish? Drug testing bench to bedside with IPS cells

April 21, 2016 / Professor Paul Knoepfler, Ph.D. / 3 Comments

A new study on treating pain with a unique stem cell connection caught my attention. The paper was from a team at Pfizer led by Edward B. Stevens. Talk about bench to bedside, these researchers went all the way from patients to patient somatic cells to reprogrammed IPSC to neurons to model pain in a dish

Pain in a dish? Drug testing bench to bedside with IPS cells Read More »

New Mitalipov paper on stem cell mitochondria: challenge for IPS cell field?

April 15, 2016 / Professor Paul Knoepfler, Ph.D. / 11 Comments

A new paper from Shoukhrat Mitalipov’s lab on stem cell mitochondria points to a pattern whereby induced pluripotent stem (IPS) cells tend to have more problems if they are from older patients. New Mitalipov paper What does this paper mean for the stem cell field and could it impact more specifically the clinical applications of IPS

New Mitalipov paper on stem cell mitochondria: challenge for IPS cell field? Read More »

For IPS cell mutations, some reassuring new data but validation still key

February 24, 2016 / Professor Paul Knoepfler, Ph.D. / 2 Comments

Over the years some scientists including yours truly have expressed concerns about the possibility that mutations could crop up during the reprogramming process to make induced pluripotent stem cells (IPS cells or IPSC). How concerned should we be about IPS cell mutations? A cool new paper, Bhutani, et al, in Nature Communications from a team led by

For IPS cell mutations, some reassuring new data but validation still key Read More »

World Stem Cell Summit 2015: IPS cells, #CRISPR, CAR-T

December 11, 2015 / Professor Paul Knoepfler, Ph.D. / 4 Comments

It’s been a great couple days so far here at the World Stem Cell Summit in Atlanta. You can follow it on Twitter using the #WSCS15 hash tag. I first attended it 5 years ago in Pasadena. One of the special aspects of WSCS is it brings together diverse stakeholders in a way that just

World Stem Cell Summit 2015: IPS cells, #CRISPR, CAR-T Read More »

Parkinson’s IPS cell trial in Japan switching to allogeneic

November 15, 2015 / Professor Paul Knoepfler, Ph.D. / 21 Comments

What’s better for stem cell trials such as for vision loss or Parkinson’s Disease: allogeneic or autologous cells? In a major shift earlier this year, the induced pluripotent stem (IPS) cell trial in Japan for treatment of macular degeneration (MD) switched gears from using the patients’ own cells (called “autologous”) to using banked cells from

Parkinson’s IPS cell trial in Japan switching to allogeneic Read More »

IPS Cell Immunogenicity, Clinical Insights, & Possible Solutions

August 23, 2015 / Professor Paul Knoepfler, Ph.D. / 2 Comments

Can cells produced from autologous induced pluripotent stem cell (IPSC or IPS cell) cultures sometimes be immunogenic in patients? This key question has remained somewhat unsettled due to varied findings over the years (e.g. see here), but many of us had generally felt in the last couple years that IPS cell derivative immunogenicity in an

IPS Cell Immunogenicity, Clinical Insights, & Possible Solutions Read More »

Historic turning point for IPS cell field in Japan?

August 2, 2015 / Professor Paul Knoepfler, Ph.D. / 24 Comments

As many of you know, the pioneering, first of its kind IPS cell clinical study in Japan has been suspended as I first blogged about here.2020 Update: I believe a version of this study is ongoing. In the comments section of that blog post there has been a helpful overall discussion that has involved Dr.

Historic turning point for IPS cell field in Japan? Read More »

Lessons from New IPS Cell Study Showing Tumors

February 17, 2015 / Professor Paul Knoepfler, Ph.D. / 11 Comments

A cool new paper is out in Stem Cell Reports describing long-term tumorigenicity of human induced pluripotent stem cells (IPSC or IPS cells). See graphical abstract. The potential tumorigenicity of IPSC is a major concern when teams around the world are translating IPSC technology to the bedside. Past studies including one from my own lab have

Lessons from New IPS Cell Study Showing Tumors Read More »

Search Results for: ips cell